| In silico Methods for Design of Kinase Inhibitors as Anticancer Drugs Z Gagic, D Ruzic, N Djokovic, T Djikic, K Nikolic Frontiers in chemistry 7, 873, 2020 | 87 | 2020 |
| Modulating protein–protein interactions with visible‐light‐responsive peptide backbone photoswitches L Albert, A Peñalver, N Djokovic, L Werel, M Hoffarth, D Ruzic, J Xu, ... ChemBioChem 20 (11), 1417-1429, 2019 | 40 | 2019 |
| Targeting histone deacetylases: opportunities for cancer treatment and chemoprevention D Ruzic, N Djoković, T Srdić-Rajić, C Echeverria, K Nikolic, JF Santibanez Pharmaceutics 14 (1), 209, 2022 | 29 | 2022 |
| Combined Ligand and Fragment‐based Drug Design of Selective Histone Deacetylase–6 Inhibitors D Ruzic, M Petkovic, D Agbaba, A Ganesan, K Nikolic Molecular Informatics 38 (5), 1800083, 2019 | 24 | 2019 |
| Quantitative structure-retention relationship of selected imidazoline derivatives on α1-acid glycoprotein column S Filipic, D Ruzic, J Vucicevic, K Nikolic, D Agbaba Journal of Pharmaceutical and Biomedical Analysis 127, 101-111, 2016 | 24 | 2016 |
| Bistable photoswitch allows in vivo control of hematopoiesis L Albert, J Nagpal, W Steinchen, L Zhang, L Werel, N Djokovic, D Ruzic, ... ACS central science 8 (1), 57-66, 2021 | 18 | 2021 |
| In silico identification of novel 5-HT2A antagonists supported with ligand- and target-based drug design methodologies M Radan, D Ruzic, M Antonijevic, T Djikic, K Nikolic Journal of Biomolecular Structure and Dynamics 39 (5), 1819-1837, 2021 | 15 | 2021 |
| Structure-based design of selective histone deacetylase 6 zinc binding groups LA Alves Avelar, D Ruzic, N Djokovic, T Kurz, K Nikolic Journal of Biomolecular Structure and Dynamics 38 (11), 3166-3177, 2020 | 11 | 2020 |
| Anticancer evaluation of the selected tetrahydropyrimidines: 3D-QSAR, cytotoxic activities, mechanism of action, DNA, and BSA interactions E Milović, J Petronijević, N Joksimović, M Beljkaš, D Ružić, K Nikolić, ... Journal of Molecular Structure 1257, 132621, 2022 | 10 | 2022 |
| Fragment-based drug design of selective HDAC6 inhibitors D Ruzic, N Djokovic, K Nikolic Protein-Ligand Interactions and Drug Design, 155-170, 2021 | 10 | 2021 |
| Dual LSD1 and HDAC6 inhibition induces doxorubicin sensitivity in acute myeloid leukemia cells I Bulut, A Lee, B Cevatemre, D Ruzic, R Belle, A Kawamura, S Gul, ... Cancers 14 (23), 6014, 2022 | 9 | 2022 |
| Discovery of 1-benzhydryl-piperazine-based HDAC inhibitors with anti-breast cancer activity: synthesis, molecular modeling, in vitro and in vivo biological evaluation D Ruzic, B Ellinger, N Djokovic, JF Santibanez, S Gul, M Beljkas, A Djuric, ... Pharmaceutics 14 (12), 2600, 2022 | 9 | 2022 |
| Extending cross metathesis to identify selective HDAC inhibitors: synthesis, biological activities, and modeling S Bouchet, C Linot, D Ruzic, D Agbaba, B Fouchaq, J Roche, K Nikolic, ... ACS Medicinal Chemistry Letters 10 (6), 863-868, 2019 | 9 | 2019 |
| An Integrative in silico Drug Repurposing Approach for Identification of Potential Inhibitors of SARS‐CoV‐2 Main Protease N Djokovic, D Ruzic, T Djikic, S Cvijic, J Ignjatovic, S Ibric, K Baralic, ... Molecular Informatics 40 (5), 2000187, 2021 | 8 | 2021 |
| Expanding the Accessible Chemical Space of SIRT2 Inhibitors through Exploration of Binding Pocket Dynamics N Djokovic, D Ruzic, M Rahnasto-Rilla, T Srdic-Rajic, ... Journal of Chemical Information and Modeling 62 (10), 2571-2585, 2022 | 6 | 2022 |
| Synthesis and biological activity of a cytostatic inhibitor of MLLr leukemia targeting the DOT1L protein C Bon, Y Si, M Pernak, M Barbachowska, E Levi-Acobas, V Cadet Daniel, ... Molecules 26 (17), 5300, 2021 | 5 | 2021 |
| Correlating basal gene expression across chemical sensitivity data to screen for novel synergistic interactors of HDAC inhibitors in pancreatic carcinoma N Djokovic, A Djuric, D Ruzic, T Srdic-Rajic, K Nikolic Pharmaceuticals 16 (2), 294, 2023 | 3 | 2023 |
| Medicinal chemistry of histone deacetylase inhibitors ZV D. Ruzic, N. Djokovic, K. Nikolic Archives of Pharmacy, https://aseestant.ceon.rs/index.php/arhf, 2021 | 2* | 2021 |
| Discovery of 1-benzhydryl piperazine-based HDAC inhibitors with anti-cancer and anti-metastatic properties against human breast cancer: synthesis, molecular modeling, in vitro … D Ruzic, M Petkovic, N Djokovic, J Santibanez, B Ellinger, M Beljkas, ... | 1 | 2022 |
| Design of Dual COX-2 and 5-LOX Inhibitors with Iron-Chelating Properties Using Structure-Based and Ligand-Based Methods J Bošković, D Ružić, O Čudina, K Nikolic, V Dobričić Letters in Drug Design & Discovery 19 (4), 279-292, 2022 | 1 | 2022 |
